ArticleFrontiers in oncology2025
Development of a machine learning model for predicting the expression of proteins associated with targeted therapy in endometrial cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Radiology-based artificial intelligence for predicting targeted therapy response in pan-cancer: a comprehensive review.Journal of translational medicine · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To develop a machine learning model integrates multi-parametric magnetic resonance imaging (MRI) radiomics features and clinicopathological features to predict the expression status of phosphatase and tension homolog (PTEN), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), and mammalian target of rapamycin (mTOR), which are frequently linked with targeted therapy for endometrial cancer (EC), in order to establish a dependable foundation for personalized adjuvant therapy for EC patients. Methods: we retrospectively recruited 82 EC patients who underwent preoperative MRI and radical resection at two independent hospitals. 60 patients from Center 1 were utilized as the training set for constructing the machine learning model, while 22 patients from Center 2 served as an external validation set to assess the model's performance. We evaluated the performance of models predicted three proteins' expression using receiver operating characteristic (ROC) analysis, calibration curve analysis, and decision curve analysis (DCA). Result: To construct machine learning models for predicting the expression of PTEN, PIK3CA, and mTOR, we respectively screened 5 radiomic and 7 clinicopathologic features, 4 radiomic and 9 clinicopathologic features, and 2 radiomic and 10 clinicopathologic features. The area under the curve (AUC) values of the radscore, clinicopathology, and combination models predicting PTEN expression were 0.875, 0.703, and 0.891 in the training set, and 0.750, 0.844, and 0.833 in the validation set, respectively. The AUC values for the models predicted PIK3CA expression in the training set were 0.856, 0.633, and 0.880, respectively, in the validation set, they were 0.842, 0.667, and 0.825. The AUC of each model for mTOR were 0.896, 0.831, and 0.912 in the training set, and 0.729, 0.847, and 0.829 in the validation set. Calibration curve analysis and DCA showed that the combination models were both well calibrated and clinically useful. Conclusion: Machine learning models integrating multi-parametric MRI radiomics and clinicopathological features can be a potential tool for predicting PTEN, PIK3CA, and mTOR expression status in EC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.